The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Oral Miltefosine for Indian Visceral Leishmaniasis
Open accessAbstract
BACKGROUND: There are 500,000 cases per year of visceral leishmaniasis, which occurs primarily in the Indian subcontinent. Almost all untreated patients die, and all the effective agents have been parenteral. Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis. We performed a clinical trial in India comparing miltefosine with the most effective standard treatment, amphotericin B. METHODS: The study was a randomized, open-label comparison, in which 299 patients 12 years of age or older received orally administered miltefosine (50 or 100 mg [approximately 2.5 mg per kilogram of body weight] daily for 28 days) and 99 patients received intravenously administered amphotericin B (1 mg per kilogram every other day for a total of 15 injections). RESULTS: The groups were well matched in terms of age, weight, proportion with previous failure of treatment for leishmaniasis, parasitologic grade of splenic aspirate, and splenomegaly. At the end of treatment, splenic aspirates were obtained from 293 patients in the miltefosine group and 98 patients in the amphotericin B group. No parasites were identified, for an initial cure rate of 100 percent. By six months after the completion of treatment, 282 of the 299 patients in the miltefosine group (94 percent [95 percent confidence interval, 91 to 97]) and 96 of the 99 patients in the amphotericin B group (97 percent) had not had a relapse; these patients were classified as cured. Vomiting and diarrhea, generally lasting one to two days, occurred in 38 percent and 20 percent of the patients in the miltefosine group, respectively. CONCLUSIONS: Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis. Miltefosine may be particularly advantageous because it can be administered orally. It may also be helpful in regions where parasites are resistant to current agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herwaldt, B. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10178-2 · Cited by 1,229
Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years
Berman, J. D. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.684 · Cited by 806
Self-citationFarrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Desjeux, P. (1996) · Clinics in Dermatology · doi:10.1016/0738-081x(96)00057-0 · Cited by 585
Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis
Jha, T. K., Sundar, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., & Berman, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412403 · Cited by 468
Self-citationTrial of oral miltefosine for visceral leishmaniasis
Sundar, S., Rosenkaimer, F., Makharia, M. K., Goyal, A. K., Mandal, A. K., Voss, A., Hilgard, P., & Murray, H. W. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04367-0 · Cited by 244
Self-citationJha, T. K., Olliaro, P., Thakur, C. P. N., Kanyok, T. P., Singhania, B. L., Singh, I. J., Singh, N. K. P., Akhoury, S., Jha, S., & Lockwood, D. N. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1200 · Cited by 170
Self-citationSundar, S., Lockwood, D. N. J., Agrawal, G., Rai, M., Makharia, M. K., & Murray, H. W. (2001) · BMJ · doi:10.1136/bmj.323.7310.419 · Cited by 165
Self-citationChanging response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Sn, J., Singh, N. K., & Tk, J. (1991) · PubMed · Cited by 85
Cited by
Murray, H. W., Berman, J. D., Davies, C. R., & Saravia, N. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67629-5 · Cited by 1,771
Self-citationDrug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
Self-citationNatural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Torres-Guerrero, E., Quintanilla-Cedillo, M. R., Ruiz-Esmenjaud, J., & Arenas, R. (2017) · F1000Research · doi:10.12688/f1000research.11120.1 · Cited by 1,066
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M. P., López-Vélez, R., García-Hernández, R., Pountain, A. W., Mwenechanya, R., & Papadopoulou, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006052 · Cited by 962
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
Feasey, N., Wansbrough-Jones, M., Mabey, D. C. W., & Solomon, A. W. (2010) · British Medical Bulletin · doi:10.1093/bmb/ldp046 · Cited by 817
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Injectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
Self-citationAronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E. M., Ephros, M., Jeronimo, S., & Magill, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw670 · Cited by 458
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 434
Self-citationLeishmaniasis chemotherapy—challenges and opportunities
Croft, S. L., & Olliaro, P. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03630.x · Cited by 424
Miltefosine for New World Cutaneous Leishmaniasis
Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Vega, J. C., Diaz, A., Luz, M., Gutierrez, P., Arboleda, M., Berman, J. D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/383321 · Cited by 385
Self-citationRecent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Self-citationThe use of unequal randomisation ratios in clinical trials: A review
Dumville, J. C., Hahn, S., Miles, J. N. V., & Torgerson, D. J. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.08.003 · Cited by 320
An update on pharmacotherapy for leishmaniasis
Sundar, S., & Chakravarty, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.973850 · Cited by 320
Self-citationRijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N. R., Dorlo, T. P. C., Beijnen, J. H., Vanaerschot, M., Decuypere, S., Dhakal, S. S., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit102 · Cited by 319
Management of trypanosomiasis and leishmaniasis
Barrett, M. P., & Croft, S. L. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds031 · Cited by 304
Challenges and new discoveries in the treatment of leishmaniasis
Singh, S., & Sivakumar, R. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-004-0348-9 · Cited by 293
Schmidt, T. J., Khalid, S. A., Romanha, A. J., Alves, T. M., Biavatti, M. W., Brun, R., Costa, F. B. D., de Castro, S. L., Ferreira, V. F., de Lacerda, M. V. G., et al. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800229023 · Cited by 262
Leishmaniasis: an update of current pharmacotherapy
Sundar, S., & Chakravarty, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.755515 · Cited by 261
Self-citationPhase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis
Bhattacharya, S. K., Sinha, P. K., Sundar, S., Thakur, C. P., Jha, T. K., Pandey, K., Das, V. R., Kumar, N., Lal, C., Verma, N., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/519690 · Cited by 261
Self-citationChemotherapy of leishmaniasis: present challenges
ULIANA, S. R. B., TRINCONI, C. T., & COELHO, A. C. (2018) · Parasitology · doi:10.1017/s0031182016002523 · Cited by 261
Virtual drug discovery and development for neglected diseases through public–private partnerships
Nwaka, S., & Ridley, R. G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1230 · Cited by 260
Recent advances and new strategies on leishmaniasis treatment
Roatt, B. M., de Oliveira Cardoso, J. M., De Brito, R. C. F., Coura-Vital, W., de Oliveira Aguiar-Soares, R. D., & Reis, A. B. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10856-w · Cited by 253
Liposomal amphotericin B and leishmaniasis: Dose and response
Sundar, S., & Chakravarty, J. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62886 · Cited by 217
Self-citationWall, G., Herrera, N., & Lopez-Ribot, J. L. (2019) · Journal of Fungi · doi:10.3390/jof5040092 · Cited by 58
Metadata
- Authors
- Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-11-28
- Volume
- 347
- Issue
- 22
- Pages
- 1739-1746
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2016587111
- Cited by
- 779
- References
- 9
- FWCI
- 34.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.